The group's principal activity is to develop and acquire cardiology medical devices, therapeutic devices and disposable products. The group has completed the development of an external counterpulsation device for the treatment of coronary artery disease known as the cpca 2000. The cpca 2000 counterpulsation unit is a non-invasive, atraumatic and non-toxic method of treating certain coronary disease states. Medclose is an internal puncture closure device and technique that utilizes a human glue deployment to close puncture wounds following surgery. Medclose is in the development stage.
